Retatrutida
GIP/GLP-1/glucagon triple agonist
Triple agonist in clinical development for obesity and metabolism.
Back to technical sheets- Class
- GIP/GLP-1/glucagon triple agonist
- Also known as
- Investigational compound (not approved)
Mechanism of action
Simultaneously activates the GIP, GLP-1 and glucagon receptors. The added glucagon component aims to raise energy expenditure on top of the incretin effects on satiety and glycemia.
Evidence
In clinical research (phase 2/3 trials). Preliminary weight-loss results are striking but still need confirmation in longer, safety-focused studies. Not approved.
Studied uses
- Obesity (under study)
- Metabolic disorders (under study)
Safety considerations
- Long-term safety profile still under evaluation
- Glucagon agonism requires glycemic monitoring
- Not available for approved clinical use
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Presentation
- Polvo liofilizado en vial sellado
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.